DGFT amends the Export Policy of APIs and formulations made from these APIs

Mar 04, 2020 | by Avantis RegTech Legal Research Team

Finance & Taxation Compliance

The Directorate general of Foreign Trade (DGFT) on March 03, 2020, has made amendment, with immediate effect in Chapter 29 (Organic Chemicals) and Chapter 30 (Pharmaceutical) of the Schedule 2 of the ITC (HS) Export Policy 2018, to restricts the export of specified Active Pharmaceutical Ingredients and formulations.

Description of the items are as under:

Paracetamol; Tinidazole; Metronidazole; Acyclovir; Vitamin B1; Vitamin B6; Vitamin B12; Progesterone; Chloramphenicol; Erythromycin Salts; Neomycin; Clindamycin Salts; Ornidazole; Formulations made of Progestrone; Formulations made of Vitamin B1; Formulations made of Vitamin B12; Formulations made of Vitamin B6; Formulations made of Neomycin; Formulations made of Metronidazole; formulations made of Tinidazole; Formulations made of Acyclovir; Formulations made of Paracetamol.

Effect of this Notification:

Export of specified APIs (Active Pharmaceutical Ingredients) and formulations made from these APIs under the ITC HS Codes mentioned against each is hereby ‘restricted’ with immediate effect and till further orders.

[Notification No. 50/2015-2020]


Related Updates

Alternate Text

Get updates on the go on RuleZbook Mobile App.